Biotech company from Sweden, OxThera, Raises EUR 32 Million.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announced that it has agreed on a EURO 32 million investment to complete the Oxabact development program for treatment of Primary hyperoxaluria.
The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, France, Idinvest Partners, France, Stiftelsen Industrifonden, Sweden, and Brohuvudet, Sweden.
This announcement bolsters OxThera's position as a leader in developing therapies for Primary hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
OxThera was founded in 2005 and had raised almost $50M prior to this financing round.